GlassScriptPhysician profile
Steven O Podolsky
NPI 1013949650
$501.66
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $354 · 2020: $85.72 · 2021: $62.13.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $232.04 | 2019-2021 | |
| Astellas Pharma US INC | $57.48 | 2019-2020 | |
| Hologic Sales and Service, LLC | $34.70 | 2019 | |
| Shire North American Group INC | $30.45 | 2019 | |
| Amag Pharmaceuticals, INC. | $27.06 | 2019-2020 | |
| Minerva Surgical, INC | $24.97 | 2021 | |
| Daiichi Sankyo INC. | $20.62 | 2020 | |
| Organon LLC | $15.76 | 2021 | |
| Lupin INC. | $15.70 | 2020 | |
| Sage Therapeutics, LLC | $15.10 | 2020 | |
| Novo Nordisk INC | $14.94 | 2019 | |
| Boston Scientific Corporation | $12.84 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Podolsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.